Since its inception in 2017, GenFleet has built up industry-leading capabilities and expertise in developing novel drug candidates - both small molecules and biologics. Its pipeline includes many programs that have entered later-stage or pivotal clinical trials across China, the United States and Europe. Dupert? (fulzerasib) is the first approved KRAS G12C inhibitor in China and the third globally; it also received NDA priority review designation and two breakthrough therapy designations in 2023. Additionally, the first-line combination therapy of fulzerasib and cetuximab has progressed into phase II study in Europe, marking the world's first treatment integrating KRAS and EGFR inhibitors for first-line non-small cell lung cancer.
Pipeline
Patent Portfolio
R&D Staff
R&D System
Staff with Master or Doctoral Degrees
GenFleet sets up a cutting-edge pipeline of innovative therapies with a view to our prospective and highly differentiated strategy: we basically choose biological targets or pathways that have not achieved proof of concept in clinical trials across the globe. Our proprietary and fully integrated R&D platform and diversified co-development programs promote the company's continuous innovative drug discovery and clinical progress.
As our clinical trials progress with increasing global footprint, our clinical-stage products have also received continuous recognition from our partners home and abroad. The globalized efforts of clinical research and business development will also prepare GenFleet for a globalized strategy of commercialization in advance.
-874.jpg)
-592.jpg)
-989.jpg)
